Innvolution Healthcare Private Limited (IHPL), a leading innovator in medical technology solutions, today announced that it has received the manufacturing license from the Central Drugs Standard Control Organization (CDSCO) for its Cardiac Catheterization Laboratory (Cath Lab) manufacturing facility located at the Andhra Pradesh MedTech Zone (AMTZ). The regulatory approval marks a significant milestone in India’s journey towards strengthening domestic capabilities in advanced cardiac imaging and intervention technologies. The facility, recently inaugurated by the Hon’ble Union Minister of Commerce & Industry, Shri Piyush Goyal, represents a major step forward in enabling indigenous manufacturing of sophisticated medical equipment aligned with the Government of India’s Make in India initiative.
Cardiovascular diseases continue to pose a significant healthcare challenge in India, impacting an estimated 80 million people and contributing to nearly three million deaths annually. With approximately 4,000 operational cardiac catheterization laboratories across the country, access to advanced cardiac procedures remains limited, particularly in regions beyond major urban centres.
The establishment of locally manufactured Cath Lab systems is expected to support healthcare providers by improving affordability, strengthening supply chain resilience, reducing import dependence, and expanding access to advanced cardiac care. With rising investments in healthcare infrastructure and increasing demand for minimally invasive procedures, India’s cardiac care ecosystem is emerging as one of the fastest-growing segments within the medical device industry.
Globally, the cardiac Cath Lab equipment and consumables market is projected to expand from approximately USD 30–32 billion in 2026 to USD 50–55 billion over the next decade, creating significant opportunities for innovation and technology development. IHPL’s manufacturing capability at AMTZ positions India to participate more actively in this growing global market while building domestic expertise in high-value medical technologies.
Dr Jitendra Sharma, MD & Founder CEO, AMTZ, said, “The approval of Innvolution Healthcare’s Cath Lab manufacturing facility is a testament to the strength of India’s emerging MedTech ecosystem. AMTZ continues to provide an enabling environment for innovation, manufacturing excellence and regulatory advancement, helping India establish itself as a global hub for medical technology.”
Gaurav Agarwal, Managing Director, Innvolution Healthcare Private Limited, said, “The CDSCO manufacturing license marks a transformative milestone in our mission to develop advanced healthcare technologies from India. The world-class infrastructure and ecosystem at AMTZ have played a vital role in establishing our Cath Lab manufacturing capabilities. We are committed to delivering reliable, high-quality solutions that address critical healthcare needs in India and across global markets.”
The collaboration between AMTZ and Innvolution Healthcare demonstrates the potential of public-private partnerships in accelerating healthcare innovation and manufacturing. This achievement reinforces India’s commitment to medical technology self-reliance while supporting improved access to advanced cardiac care and strengthening the nation’s position in the global MedTech landscape.
Innvolution Healthcare Private Limited develops advanced medical technology solutions focused on improving clinical outcomes and expanding access to innovative healthcare systems. Through indigenous research, engineering and manufacturing capabilities, the company is committed to advancing healthcare delivery in India and globally.
Andhra Pradesh MedTech Zone (AMTZ) is India’s premier medical technology manufacturing ecosystem, established to enable innovation, research, development and production of advanced medical devices through integrated infrastructure and industry support.
